Market Summary
USD55.52+1.24
Market Closed2.28%
OMCL Stock Price
OMCL RSI Chart
OMCL Valuation
OMCL Price/Sales (Trailing)
OMCL Profitability
OMCL Fundamentals
OMCL Revenue
OMCL Earnings
Price Action
52 Week Range
46.11133.03
(Low)(High)
Last 7 days
-0.4%
Last 30 days
4.8%
Last 90 days
12.9%
Trailing 12 Months
-58.3%
OMCL Financial Health
OMCL Investor Care
Peers (Alternatives to Omnicell)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 180.2B | 31.5B | -0.19% | -16.26% | 25 | 5.73 | 6.85% | 12.06% |
MDT | 105.2B | 30.8B | -5.18% | -29.10% | 25.88 | 3.42 | -3.19% | -17.38% |
CERN | 27.9B | - | 0.98% | 20.75% | 47.36 | 4.81 | - | - |
VEEV | 27.8B | 2.1B | 7.79% | -16.97% | 70.06 | 13.37 | 17.88% | -8.53% |
| MID-CAP | ||||||||
CHNG | 9.0B | 3.5B | 11.88% | 31.28% | -116.8 | 2.57 | 7.15% | -34.72% |
INSP | 7.0B | 407.9M | -8.38% | -7.60% | -156.41 | 17.21 | 74.75% | -6.75% |
TDOC | 4.1B | 2.4B | -7.30% | -67.14% | -0.3 | 1.69 | 18.41% | -3085.58% |
OMCL | 2.5B | 1.3B | 4.83% | -58.32% | 439.86 | 1.92 | 14.48% | -92.74% |
| SMALL-CAP | ||||||||
PHR | 1.6B | 262.3M | -14.74% | 2.84% | -8.77 | 6.17 | 33.16% | -131.28% |
SDGR | 1.5B | 181.0M | 14.61% | -31.64% | -10.26 | 8.46 | 31.19% | -48.60% |
OPRX | 261.9M | 63.1M | -18.62% | -64.97% | -24.97 | 4.15 | 9.93% | -1043.45% |
TRHC | 136.8M | 357.1M | -19.59% | -15.27% | -0.98 | 0.38 | 33.22% | -57.66% |
ICAD | 32.1M | 29.3M | -53.48% | -70.87% | -2.18 | 1.1 | -19.35% | -69.01% |
HTGM | 3.4M | 6.8M | 10.81% | 132.08% | -0.15 | 0.5 | -21.00% | -36.01% |
Financials for Omnicell
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -1.0% | 1,296 | 1,309 | 1,258 | 1,199 | 1,132 |
| Gross Profit | -4.5% | 589 | 617 | 604 | 582 | 555 |
| Operating Expenses | 3.9% | 591 | 569 | 546 | 507 | 465 |
| S&GA Expenses | 3.4% | 486 | 470 | 453 | 423 | 389 |
| R&D Expenses | 6.6% | 105 | 99.00 | 93.00 | 85.00 | 76.00 |
| EBITDA | -32.2% | 84.00 | 125 | 127 | 111 | - |
| EBITDA Margin | -31.5% | 0.07* | 0.10* | 0.10* | 0.09* | - |
| Earnings Before Taxes | -106.2% | -2.45 | 40.00 | 46.00 | 58.00 | 66.00 |
| EBT Margin | -106.2% | 0.00* | 0.03* | 0.04* | 0.05* | - |
| Interest Expenses | - | 2.00 | - | - | - | - |
| Net Income | -88.2% | 6.00 | 48.00 | 61.00 | 72.00 | 78.00 |
| Net Income Margin | -88.1% | 0.00* | 0.04* | 0.05* | 0.06* | - |
| Free Cahsflow | 193.0% | 30.00 | 10.00 | 38.00 | 123 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 1.4% | 2,211 | 2,180 | 2,131 | 2,123 | 2,142 |
| Current Assets | 3.8% | 882 | 849 | 788 | 776 | 781 |
| Cash Equivalents | 32.4% | 353 | 266 | 245 | 265 | 349 |
| Inventory | 0.3% | 148 | 147 | 150 | 137 | 120 |
| Net PPE | 6.3% | 94.00 | 88.00 | 82.00 | 77.00 | 71.00 |
| Goodwill | 0.4% | 734 | 731 | 734 | 740 | 739 |
| Liabilities | 3.5% | 1,081 | 1,044 | 1,039 | 1,048 | 996 |
| Current Liabilities | 13.7% | 428 | 377 | 374 | 951 | 876 |
| Shareholder's Equity | -0.5% | 1,130 | 1,135 | 1,093 | 1,075 | 1,147 |
| Retained Earnings | -6.8% | 391 | 419 | 402 | 393 | 369 |
| Additional Paid-In Capital | 1.6% | 1,047 | 1,031 | 998 | 983 | 1,025 |
| Accumulated Depreciation | -5.5% | 123 | 130 | 126 | 122 | - |
| Shares Outstanding | 0.2% | 45.00 | 45.00 | 44.00 | 44.00 | 44.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 40.8% | 78.00 | 55.00 | 77.00 | 158 | 232 |
| Share Based Compensation | 4.3% | 68.00 | 65.00 | 62.00 | 58.00 | 53.00 |
| Cashflow From Investing | 74.9% | -58.67 | -233 | -411 | -418 | -412 |
| Cashflow From Financing | -17.4% | -20.95 | -17.85 | -8.62 | -0.35 | 47.00 |
| Buy Backs | 0% | 52.00 | 52.00 | 52.00 | 52.00 | 0.00 |
Risks for OMCL
What is the probability of a big loss on OMCL?
81.2%
Probability that Omnicell stock will be more than 20% underwater in next one year
41.9%
Probability that Omnicell stock will be more than 30% underwater in next one year.
18.9%
Probability that Omnicell stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does OMCL drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Omnicell was unfortunately bought at previous high price.
Drawdowns
Returns for OMCL
Cumulative Returns on OMCL
11.4%
10-Year Cumulative Returns
10.6%
7-Year Cumulative Returns
5.1%
5-Year Cumulative Returns
-0.8%
3-Year Cumulative Returns
What are the long-term rolling returns for OMCL?
FIve years rolling returns for Omnicell.
Annualized Returns
Which funds bought or sold OMCL recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | reduced | -0.68 | -1,873,600 | 2,539,000 | 0.02% |
2023-03-17 | American Portfolios Advisors | reduced | -2.99 | -93,291 | 268,662 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -4.58 | -1,713,550 | 2,118,450 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -86.79 | -20,800,000 | 1,722,000 | 0.01% |
2023-02-28 | Voya Investment Management LLC | added | 103 | 260,835 | 1,732,840 | -% |
2023-02-24 | NATIXIS | added | 92.73 | 57,737 | 754,737 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -12.32 | -1,152,000 | 1,191,000 | 0.01% |
2023-02-21 | NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC | reduced | -35.39 | -348,614 | 208,386 | 0.01% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | added | 1.14 | -145,682 | 206,318 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -40.28 | -68,774,000 | 36,364,000 | 0.04% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Omnicell News
Schedule 13G FIlings of Omnicell
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.92% | 4,430,315 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 7.34% | 3,277,600 | SC 13G/A | |
| Jan 23, 2023 | blackrock inc. | 12.8% | 5,728,315 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 10.79% | 4,740,493 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 5.76% | 2,531,555 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 15.9% | 6,983,442 | SC 13G/A | |
| Jan 26, 2022 | blackrock inc. | 15.9% | 6,983,442 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 10.62% | 4,492,384 | SC 13G/A | |
| Feb 05, 2021 | blackrock inc. | 15.7% | 6,663,069 | SC 13G/A | |
| Jan 11, 2021 | wellington management group llp | 6.04% | 2,555,699 | SC 13G/A |
OMCL Fair Value
Omnicell fair value in different scenarios
The table shows the Fair Value estimates for Omnicell for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 26.61 -52.07% | 32.03 -42.31% | 42.64 -23.20% | 57.13 2.90% | 67.72 21.97% |
| Current Inflation | 24.79 -55.35% | 29.39 -47.06% | 38.30 -31.02% | 50.45 -9.13% | 59.26 6.74% |
| Very High Inflation | 22.54 -59.40% | 26.20 -52.81% | 33.19 -40.22% | 42.70 -23.09% | 49.55 -10.75% |
Historical Omnicell Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Omnicell
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 17, 2023 | 4 | Insider Trading | |
| Mar 17, 2023 | 4 | Insider Trading | |
| Mar 09, 2023 | 4 | Insider Trading | |
| Mar 01, 2023 | 10-K | Annual Report | |
| Feb 28, 2023 | 8-K | Current Report | |
| Feb 17, 2023 | 4 | Insider Trading | |
| Feb 14, 2023 | 5 | Insider Trading | |
| Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 06, 2023 | SC 13G/A | Major Ownership Report | |
| Jan 23, 2023 | SC 13G/A | Major Ownership Report |
Latest Insider Trading transactions for OMCL
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-15 | SPEARS JOSEPH BRIAN | sold (taxes) | -6,023 | 55.26 | -109 | chief accounting officer & svp |
2023-03-15 | Manley Corey J | sold (taxes) | -4,586 | 55.26 | -83.00 | sr. vp & chief legal officer |
2023-03-07 | Bauer Joanne B | sold | -711,333 | 54.2381 | -13,115 | - |
2023-03-07 | Bauer Joanne B | acquired | 493,469 | 25.53 | 19,329 | - |
2023-02-15 | SPEARS JOSEPH BRIAN | sold (taxes) | -3,259 | 55.25 | -59.00 | chief accounting officer & svp |
2022-12-28 | PARRISH MARK W | acquired | 44,610 | 14.87 | 3,000 | - |
2022-12-27 | Seidelmann Scott Peter | sold | -45,624 | 48.28 | -945 | evp, chief commercial officer |
2022-12-22 | PARRISH MARK W | acquired | 44,610 | 14.87 | 3,000 | - |
2022-12-16 | Seidelmann Scott Peter | sold | -211,990 | 47.7885 | -4,436 | evp, chief commercial officer |
2022-12-15 | Manley Corey J | sold (taxes) | -10,753 | 48.44 | -222 | sr. vp & chief legal officer |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
OMCL Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues | $ 1,295,947 | $ 1,132,018 | $ 892,208 |
| Cost of revenues | 706,960 | 577,365 | 478,916 |
| Gross profit | 588,987 | 554,653 | 413,292 |
| Operating expenses: | |||
| Research and development | 104,969 | 75,716 | 70,161 |
| Selling, general, and administrative | 486,341 | 389,430 | 307,605 |
| Total operating expenses | 591,310 | 465,146 | 377,766 |
| Income (loss) from operations | (2,323) | 89,507 | 35,526 |
| Interest and other income (expense), net | (130) | (23,500) | (6,177) |
| Income (loss) before provision for income taxes | (2,453) | 66,007 | 29,349 |
| Benefit from income taxes | (8,101) | (11,842) | (2,845) |
| Net income | $ 5,648 | $ 77,849 | $ 32,194 |
| Net income per share: | |||
| Basic (in dollars per share) | $ 0.13 | $ 1.79 | $ 0.76 |
| Diluted (in dollars per share) | $ 0.12 | $ 1.62 | $ 0.74 |
| Weighted-average shares outstanding: | |||
| Basic (in shares) | 44,398 | 43,475 | 42,583 |
| Diluted (in shares) | 45,891 | 47,943 | 43,743 |
| Product revenues | |||
| Revenues | $ 903,222 | $ 812,512 | $ 636,031 |
| Cost of revenues | 493,626 | 422,855 | 354,004 |
| Services and other revenues | |||
| Revenues | 392,725 | 319,506 | 256,177 |
| Cost of revenues | $ 213,334 | $ 154,510 | $ 124,912 |
OMCL Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 330,362 | $ 349,051 |
| Accounts receivable and unbilled receivables, net of allowances of $5,153 and $5,272, respectively | 299,469 | 240,894 |
| Inventories | 147,549 | 119,924 |
| Prepaid expenses | 27,070 | 22,499 |
| Other current assets | 77,362 | 48,334 |
| Total current assets | 881,812 | 780,702 |
| Property and equipment, net | 93,961 | 71,141 |
| Long-term investment in sales-type leases, net | 32,924 | 18,391 |
| Operating lease right-of-use assets | 38,052 | 48,549 |
| Goodwill | 734,274 | 738,900 |
| Intangible assets, net | 242,906 | 277,616 |
| Long-term deferred tax assets | 22,329 | 15,883 |
| Prepaid commissions | 59,483 | 63,795 |
| Other long-term assets | 105,017 | 127,519 |
| Total assets | 2,210,758 | 2,142,496 |
| Current liabilities: | ||
| Accounts payable | 63,389 | 71,513 |
| Accrued compensation | 73,455 | 71,130 |
| Accrued liabilities | 172,655 | 133,167 |
| Deferred revenues, net | 118,947 | 112,196 |
| Convertible senior notes, net | 0 | 488,152 |
| Total current liabilities | 428,446 | 876,158 |
| Long-term deferred revenues | 37,385 | 20,194 |
| Long-term deferred tax liabilities | 2,095 | 51,705 |
| Long-term operating lease liabilities | 39,405 | 39,911 |
| Other long-term liabilities | 6,719 | 7,839 |
| Convertible senior notes, net | 566,571 | 0 |
| Total liabilities | 1,080,621 | 995,807 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued | 0 | 0 |
| Common stock, $0.001 par value, 100,000 shares authorized; 55,030 and 54,073 shares issued; 44,747 and 44,179 shares outstanding, respectively | 55 | 54 |
| Treasury stock at cost, 10,283 and 9,894 shares outstanding, respectively | (290,319) | (238,109) |
| Additional paid-in capital | 1,046,760 | 1,024,580 |
| Retained earnings | 390,728 | 368,571 |
| Accumulated other comprehensive loss | (17,087) | (8,407) |
| Total stockholders’ equity | 1,130,137 | 1,146,689 |
| Total liabilities and stockholders’ equity | $ 2,210,758 | $ 2,142,496 |
| Treasury stock, shares outstanding (in shares) | 10,283 | 9,894 |